Role of LPS-elicited signaling in triggering gastric mucosal inflammatory responses to H. pylori: modulatory effect of ghrelin

Infection with Helicobacter pylori is a primary culprit in the etiology of gastric disease, and its cell-wall lipopolysaccharide (LPS) is recognized as a potent endotoxin responsible for triggering a pattern of the mucosal inflammatory responses. The engagement by the LPS of gastric mucosal Toll-lik...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Inflammopharmacology 2017-08, Vol.25 (4), p.415-429
Hauptverfasser: Slomiany, B. L., Slomiany, A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 429
container_issue 4
container_start_page 415
container_title Inflammopharmacology
container_volume 25
creator Slomiany, B. L.
Slomiany, A.
description Infection with Helicobacter pylori is a primary culprit in the etiology of gastric disease, and its cell-wall lipopolysaccharide (LPS) is recognized as a potent endotoxin responsible for triggering a pattern of the mucosal inflammatory responses. The engagement by the LPS of gastric mucosal Toll-like receptor 4 (TLR4) leads to initiation of signal transduction events characterized by the activation of mitogen-activated protein kinase (MAPK) cascade, induction of phosphoinositide-specific phospholipase C (PLC)/protein kinase C (PKC)/phosphatidylinositol 3-kinase (PI3K) pathway, and up-regulation in Src/Akt. These signaling events in turn exert their influence over H. pylori -elicited excessive generation of NO and PGE2 caused by the disturbances in nitric oxide synthase and cyclooxygenase isozyme systems, increase in epidermal growth factor receptor transactivation, and the induction in matrix metalloproteinase-9 (MMP-9) release. Interestingly, the extent of gastric mucosal inflammatory response to H. pylori is influenced by a peptide hormone, ghrelin, the action of which relays on the growth hormone secretagogue receptor type 1a (GHS-R1a)-mediated mobilization of G-protein dependent transduction pathways. Yet, the signals triggered by TLR-4 activation as well as those arising through GHS-R1a stimulation converge at MAPK and PLC/PKC/PI3K pathways that form a key integration node for proinflammatory signals generated by H. pylori LPS as well as for those involved in modulation of inflammation by ghrelin. Hence, therapeutic targeting these signals’ convergence and integration node could provide a novel and attractive opportunities for developing more effective treatments of H. pylori -related gastric disease.
doi_str_mv 10.1007/s10787-017-0360-1
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1900129094</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1900129094</sourcerecordid><originalsourceid>FETCH-LOGICAL-c344t-15ad809f801b907751b929e39381bee484fae4c85a874207c4ff27b0f8f17d413</originalsourceid><addsrcrecordid>eNp9kM1u1TAQRi0EopfCA7BBXrJJGSdObLNDFW2RrtSKn7Xl64yDKycOdrK4G54dRyksWYxGoznzjXQIecvgigGID5mBkKICVqrpoGLPyIG1nazaDuRzcgBVtxXvVH1BXuX8CACd6NRLclHLlnWN4Afy-2sMSKOjx4dvFQZv_YI9zX6YTPDTQP1El-SHAdM2DSaXydJxtTGbULYumHE0S0xnmjDPccqY6RLp3RWdzyEm_5GOsV_DjqBzaJft3fAzlW_Ta_LCmZDxzVO_JD9uPn-_vquO97dfrj8dK9twvlSsNb0E5SSwkwIh2tJqhY1qJDshcsmdQW5la6TgNQjLnavFCZx0TPScNZfk_Z47p_hrxbzo0WeLIZgJ45o1UwCsVqB4QdmO2hRzTuj0nPxo0lkz0Jt2vWvXRbvetOst_t1T_Hoasf938ddzAeodyPMmEpN-jGsqjvN_Uv8AB0WOsQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1900129094</pqid></control><display><type>article</type><title>Role of LPS-elicited signaling in triggering gastric mucosal inflammatory responses to H. pylori: modulatory effect of ghrelin</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Slomiany, B. L. ; Slomiany, A.</creator><creatorcontrib>Slomiany, B. L. ; Slomiany, A.</creatorcontrib><description>Infection with Helicobacter pylori is a primary culprit in the etiology of gastric disease, and its cell-wall lipopolysaccharide (LPS) is recognized as a potent endotoxin responsible for triggering a pattern of the mucosal inflammatory responses. The engagement by the LPS of gastric mucosal Toll-like receptor 4 (TLR4) leads to initiation of signal transduction events characterized by the activation of mitogen-activated protein kinase (MAPK) cascade, induction of phosphoinositide-specific phospholipase C (PLC)/protein kinase C (PKC)/phosphatidylinositol 3-kinase (PI3K) pathway, and up-regulation in Src/Akt. These signaling events in turn exert their influence over H. pylori -elicited excessive generation of NO and PGE2 caused by the disturbances in nitric oxide synthase and cyclooxygenase isozyme systems, increase in epidermal growth factor receptor transactivation, and the induction in matrix metalloproteinase-9 (MMP-9) release. Interestingly, the extent of gastric mucosal inflammatory response to H. pylori is influenced by a peptide hormone, ghrelin, the action of which relays on the growth hormone secretagogue receptor type 1a (GHS-R1a)-mediated mobilization of G-protein dependent transduction pathways. Yet, the signals triggered by TLR-4 activation as well as those arising through GHS-R1a stimulation converge at MAPK and PLC/PKC/PI3K pathways that form a key integration node for proinflammatory signals generated by H. pylori LPS as well as for those involved in modulation of inflammation by ghrelin. Hence, therapeutic targeting these signals’ convergence and integration node could provide a novel and attractive opportunities for developing more effective treatments of H. pylori -related gastric disease.</description><identifier>ISSN: 0925-4692</identifier><identifier>EISSN: 1568-5608</identifier><identifier>DOI: 10.1007/s10787-017-0360-1</identifier><identifier>PMID: 28516374</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Allergology ; Animals ; Biomedical and Life Sciences ; Biomedicine ; Dermatology ; Gastric Mucosa - drug effects ; Gastric Mucosa - metabolism ; Gastric Mucosa - microbiology ; Gastroenterology ; Ghrelin - metabolism ; Ghrelin - pharmacology ; Ghrelin - therapeutic use ; Helicobacter Infections - drug therapy ; Helicobacter Infections - metabolism ; Helicobacter pylori - drug effects ; Helicobacter pylori - isolation &amp; purification ; Humans ; Immunology ; Inflammation - chemically induced ; Inflammation - drug therapy ; Inflammation - metabolism ; Inflammation Mediators - antagonists &amp; inhibitors ; Inflammation Mediators - metabolism ; Lipopolysaccharides - toxicity ; Pharmacology/Toxicology ; Review ; Rheumatology</subject><ispartof>Inflammopharmacology, 2017-08, Vol.25 (4), p.415-429</ispartof><rights>Springer International Publishing 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c344t-15ad809f801b907751b929e39381bee484fae4c85a874207c4ff27b0f8f17d413</citedby><cites>FETCH-LOGICAL-c344t-15ad809f801b907751b929e39381bee484fae4c85a874207c4ff27b0f8f17d413</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10787-017-0360-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10787-017-0360-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28516374$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Slomiany, B. L.</creatorcontrib><creatorcontrib>Slomiany, A.</creatorcontrib><title>Role of LPS-elicited signaling in triggering gastric mucosal inflammatory responses to H. pylori: modulatory effect of ghrelin</title><title>Inflammopharmacology</title><addtitle>Inflammopharmacol</addtitle><addtitle>Inflammopharmacology</addtitle><description>Infection with Helicobacter pylori is a primary culprit in the etiology of gastric disease, and its cell-wall lipopolysaccharide (LPS) is recognized as a potent endotoxin responsible for triggering a pattern of the mucosal inflammatory responses. The engagement by the LPS of gastric mucosal Toll-like receptor 4 (TLR4) leads to initiation of signal transduction events characterized by the activation of mitogen-activated protein kinase (MAPK) cascade, induction of phosphoinositide-specific phospholipase C (PLC)/protein kinase C (PKC)/phosphatidylinositol 3-kinase (PI3K) pathway, and up-regulation in Src/Akt. These signaling events in turn exert their influence over H. pylori -elicited excessive generation of NO and PGE2 caused by the disturbances in nitric oxide synthase and cyclooxygenase isozyme systems, increase in epidermal growth factor receptor transactivation, and the induction in matrix metalloproteinase-9 (MMP-9) release. Interestingly, the extent of gastric mucosal inflammatory response to H. pylori is influenced by a peptide hormone, ghrelin, the action of which relays on the growth hormone secretagogue receptor type 1a (GHS-R1a)-mediated mobilization of G-protein dependent transduction pathways. Yet, the signals triggered by TLR-4 activation as well as those arising through GHS-R1a stimulation converge at MAPK and PLC/PKC/PI3K pathways that form a key integration node for proinflammatory signals generated by H. pylori LPS as well as for those involved in modulation of inflammation by ghrelin. Hence, therapeutic targeting these signals’ convergence and integration node could provide a novel and attractive opportunities for developing more effective treatments of H. pylori -related gastric disease.</description><subject>Allergology</subject><subject>Animals</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Dermatology</subject><subject>Gastric Mucosa - drug effects</subject><subject>Gastric Mucosa - metabolism</subject><subject>Gastric Mucosa - microbiology</subject><subject>Gastroenterology</subject><subject>Ghrelin - metabolism</subject><subject>Ghrelin - pharmacology</subject><subject>Ghrelin - therapeutic use</subject><subject>Helicobacter Infections - drug therapy</subject><subject>Helicobacter Infections - metabolism</subject><subject>Helicobacter pylori - drug effects</subject><subject>Helicobacter pylori - isolation &amp; purification</subject><subject>Humans</subject><subject>Immunology</subject><subject>Inflammation - chemically induced</subject><subject>Inflammation - drug therapy</subject><subject>Inflammation - metabolism</subject><subject>Inflammation Mediators - antagonists &amp; inhibitors</subject><subject>Inflammation Mediators - metabolism</subject><subject>Lipopolysaccharides - toxicity</subject><subject>Pharmacology/Toxicology</subject><subject>Review</subject><subject>Rheumatology</subject><issn>0925-4692</issn><issn>1568-5608</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1u1TAQRi0EopfCA7BBXrJJGSdObLNDFW2RrtSKn7Xl64yDKycOdrK4G54dRyksWYxGoznzjXQIecvgigGID5mBkKICVqrpoGLPyIG1nazaDuRzcgBVtxXvVH1BXuX8CACd6NRLclHLlnWN4Afy-2sMSKOjx4dvFQZv_YI9zX6YTPDTQP1El-SHAdM2DSaXydJxtTGbULYumHE0S0xnmjDPccqY6RLp3RWdzyEm_5GOsV_DjqBzaJft3fAzlW_Ta_LCmZDxzVO_JD9uPn-_vquO97dfrj8dK9twvlSsNb0E5SSwkwIh2tJqhY1qJDshcsmdQW5la6TgNQjLnavFCZx0TPScNZfk_Z47p_hrxbzo0WeLIZgJ45o1UwCsVqB4QdmO2hRzTuj0nPxo0lkz0Jt2vWvXRbvetOst_t1T_Hoasf938ddzAeodyPMmEpN-jGsqjvN_Uv8AB0WOsQ</recordid><startdate>20170801</startdate><enddate>20170801</enddate><creator>Slomiany, B. L.</creator><creator>Slomiany, A.</creator><general>Springer International Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170801</creationdate><title>Role of LPS-elicited signaling in triggering gastric mucosal inflammatory responses to H. pylori: modulatory effect of ghrelin</title><author>Slomiany, B. L. ; Slomiany, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c344t-15ad809f801b907751b929e39381bee484fae4c85a874207c4ff27b0f8f17d413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Allergology</topic><topic>Animals</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Dermatology</topic><topic>Gastric Mucosa - drug effects</topic><topic>Gastric Mucosa - metabolism</topic><topic>Gastric Mucosa - microbiology</topic><topic>Gastroenterology</topic><topic>Ghrelin - metabolism</topic><topic>Ghrelin - pharmacology</topic><topic>Ghrelin - therapeutic use</topic><topic>Helicobacter Infections - drug therapy</topic><topic>Helicobacter Infections - metabolism</topic><topic>Helicobacter pylori - drug effects</topic><topic>Helicobacter pylori - isolation &amp; purification</topic><topic>Humans</topic><topic>Immunology</topic><topic>Inflammation - chemically induced</topic><topic>Inflammation - drug therapy</topic><topic>Inflammation - metabolism</topic><topic>Inflammation Mediators - antagonists &amp; inhibitors</topic><topic>Inflammation Mediators - metabolism</topic><topic>Lipopolysaccharides - toxicity</topic><topic>Pharmacology/Toxicology</topic><topic>Review</topic><topic>Rheumatology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Slomiany, B. L.</creatorcontrib><creatorcontrib>Slomiany, A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Inflammopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Slomiany, B. L.</au><au>Slomiany, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of LPS-elicited signaling in triggering gastric mucosal inflammatory responses to H. pylori: modulatory effect of ghrelin</atitle><jtitle>Inflammopharmacology</jtitle><stitle>Inflammopharmacol</stitle><addtitle>Inflammopharmacology</addtitle><date>2017-08-01</date><risdate>2017</risdate><volume>25</volume><issue>4</issue><spage>415</spage><epage>429</epage><pages>415-429</pages><issn>0925-4692</issn><eissn>1568-5608</eissn><abstract>Infection with Helicobacter pylori is a primary culprit in the etiology of gastric disease, and its cell-wall lipopolysaccharide (LPS) is recognized as a potent endotoxin responsible for triggering a pattern of the mucosal inflammatory responses. The engagement by the LPS of gastric mucosal Toll-like receptor 4 (TLR4) leads to initiation of signal transduction events characterized by the activation of mitogen-activated protein kinase (MAPK) cascade, induction of phosphoinositide-specific phospholipase C (PLC)/protein kinase C (PKC)/phosphatidylinositol 3-kinase (PI3K) pathway, and up-regulation in Src/Akt. These signaling events in turn exert their influence over H. pylori -elicited excessive generation of NO and PGE2 caused by the disturbances in nitric oxide synthase and cyclooxygenase isozyme systems, increase in epidermal growth factor receptor transactivation, and the induction in matrix metalloproteinase-9 (MMP-9) release. Interestingly, the extent of gastric mucosal inflammatory response to H. pylori is influenced by a peptide hormone, ghrelin, the action of which relays on the growth hormone secretagogue receptor type 1a (GHS-R1a)-mediated mobilization of G-protein dependent transduction pathways. Yet, the signals triggered by TLR-4 activation as well as those arising through GHS-R1a stimulation converge at MAPK and PLC/PKC/PI3K pathways that form a key integration node for proinflammatory signals generated by H. pylori LPS as well as for those involved in modulation of inflammation by ghrelin. Hence, therapeutic targeting these signals’ convergence and integration node could provide a novel and attractive opportunities for developing more effective treatments of H. pylori -related gastric disease.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>28516374</pmid><doi>10.1007/s10787-017-0360-1</doi><tpages>15</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0925-4692
ispartof Inflammopharmacology, 2017-08, Vol.25 (4), p.415-429
issn 0925-4692
1568-5608
language eng
recordid cdi_proquest_miscellaneous_1900129094
source MEDLINE; SpringerNature Journals
subjects Allergology
Animals
Biomedical and Life Sciences
Biomedicine
Dermatology
Gastric Mucosa - drug effects
Gastric Mucosa - metabolism
Gastric Mucosa - microbiology
Gastroenterology
Ghrelin - metabolism
Ghrelin - pharmacology
Ghrelin - therapeutic use
Helicobacter Infections - drug therapy
Helicobacter Infections - metabolism
Helicobacter pylori - drug effects
Helicobacter pylori - isolation & purification
Humans
Immunology
Inflammation - chemically induced
Inflammation - drug therapy
Inflammation - metabolism
Inflammation Mediators - antagonists & inhibitors
Inflammation Mediators - metabolism
Lipopolysaccharides - toxicity
Pharmacology/Toxicology
Review
Rheumatology
title Role of LPS-elicited signaling in triggering gastric mucosal inflammatory responses to H. pylori: modulatory effect of ghrelin
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T00%3A20%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20LPS-elicited%20signaling%20in%20triggering%20gastric%20mucosal%20inflammatory%20responses%20to%20H.%20pylori:%20modulatory%20effect%20of%20ghrelin&rft.jtitle=Inflammopharmacology&rft.au=Slomiany,%20B.%20L.&rft.date=2017-08-01&rft.volume=25&rft.issue=4&rft.spage=415&rft.epage=429&rft.pages=415-429&rft.issn=0925-4692&rft.eissn=1568-5608&rft_id=info:doi/10.1007/s10787-017-0360-1&rft_dat=%3Cproquest_cross%3E1900129094%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1900129094&rft_id=info:pmid/28516374&rfr_iscdi=true